These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

211 related items for PubMed ID: 8650227

  • 1. Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.
    Moutouh L, Corbeil J, Richman DD.
    Proc Natl Acad Sci U S A; 1996 Jun 11; 93(12):6106-11. PubMed ID: 8650227
    [Abstract] [Full Text] [Related]

  • 2. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
    Yusa K, Kavlick MF, Kosalaraksa P, Mitsuya H.
    Antiviral Res; 1997 Dec 11; 36(3):179-89. PubMed ID: 9477118
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Selection by AZT and rapid replacement in the absence of drugs of HIV type 1 resistant to multiple nucleoside analogs.
    Lukashov VV, Huismans R, Jebbink MF, Danner SA, de Boer RJ, Goudsmit J.
    AIDS Res Hum Retroviruses; 2001 Jun 10; 17(9):807-18. PubMed ID: 11429122
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A.
    Smidt ML, Potts KE, Tucker SP, Blystone L, Stiebel TR, Stallings WC, McDonald JJ, Pillay D, Richman DD, Bryant ML.
    Antimicrob Agents Chemother; 1997 Mar 10; 41(3):515-22. PubMed ID: 9055985
    [Abstract] [Full Text] [Related]

  • 7. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
    Tisdale M, Kemp SD, Parry NR, Larder BA.
    Proc Natl Acad Sci U S A; 1993 Jun 15; 90(12):5653-6. PubMed ID: 7685907
    [Abstract] [Full Text] [Related]

  • 8. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
    de Baar MP, Janssens W, de Ronde A, Fransen K, Colebunders R, Kestens L, van der Groen G, Goudsmit J.
    AIDS Res Hum Retroviruses; 2000 Sep 20; 16(14):1385-94. PubMed ID: 11018858
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Prevalence of drug resistance mutations in B, non-B subtypes, and recombinant forms of human immunodeficiency virus type 1 in infected individuals in Spain (Galicia).
    Pérez-Alvarez L, Cuevas MT, Villahermosa ML, Pedreira JD, Manjón N, Herrero I, López-Calvo S, Delgado E, de Parga EV, Medrano L, Thomson MM, Taboada JA, Nájera R, Spanish Group for Antiretroviral Resistance Studies in Galicia.
    J Hum Virol; 2001 Sep 20; 4(1):35-8. PubMed ID: 11213931
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples.
    Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensin PE, Zazzi M.
    J Infect Dis; 2000 Feb 20; 181(2):740-5. PubMed ID: 10669367
    [Abstract] [Full Text] [Related]

  • 16. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
    Kuritzkes DR, Sevin A, Young B, Bakhtiari M, Wu H, St Clair M, Connick E, Landay A, Spritzler J, Kessler H, Lederman MM.
    J Infect Dis; 2000 Feb 20; 181(2):491-7. PubMed ID: 10669331
    [Abstract] [Full Text] [Related]

  • 17. Identification of insertion mutations in HIV-1 reverse transcriptase causing multiple drug resistance to nucleoside analogue reverse transcriptase inhibitors.
    Sugiura W, Matsuda M, Matsuda Z, Abumi H, Okano A, Oishi T, Moriya K, Yamamoto Y, Fukutake K, Mimaya J, Ajisawa A, Taki M, Yamada K, Nagai Y.
    J Hum Virol; 1999 Feb 20; 2(3):146-53. PubMed ID: 10413366
    [Abstract] [Full Text] [Related]

  • 18. Convergent combination therapy can select viable multidrug-resistant HIV-1 in vitro.
    Larder BA, Kellam P, Kemp SD.
    Nature; 1993 Sep 30; 365(6445):451-3. PubMed ID: 7692302
    [Abstract] [Full Text] [Related]

  • 19. Anti-HIV type 1 activity of 3'-fluoro-3'-deoxythymidine for several different multidrug-resistant mutants.
    Kim EY, Vrang L, Oberg B, Merigan TC.
    AIDS Res Hum Retroviruses; 2001 Mar 20; 17(5):401-7. PubMed ID: 11282008
    [Abstract] [Full Text] [Related]

  • 20. Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine.
    Kellam P, Boucher CA, Larder BA.
    Proc Natl Acad Sci U S A; 1992 Mar 01; 89(5):1934-8. PubMed ID: 1371886
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.